



sanofi

An innovative
biotechnology
company

Company brochure 2024



We chase
the miracles
of science
to improve
people's lives



We believe that our cutting-edge scientific activities and modern manufacturing processes have the potential to fundamentally transform the practice of medicine, turning the impossible into possible for millions of patients around the world.



Country Lead's message

“Discover something extraordinary. Achieve what all thought to be impossible. Make the world a better and healthier place through the miracles of science.”—these are the principles that guide us in our work here at Sanofi.

As an innovative, global biotechnology company, we offer therapeutic solutions and vaccines providing life-saving protection for millions of people worldwide. We are determined to find solutions for patients, be it in immunology, oncology, cardiovascular or rare diseases.

Our commitment to health propels us to protect hundreds of millions of people against the flu annually, and we have virtually completely eradicated polio across the world. We were the first to introduce treatment for a number of rare diseases and invented high-quality solutions to tackle diabetes and cardiovascular conditions which, by now, have become primary therapies.

It makes no difference whether we are doctors, researchers, engineers, production supervisors or salespeople as we all strive to ensure the preservation of health. We chase the miracles of science to offer people the possibility of a fulfilled life.

We believe that our cutting-edge scientific activities and modern manufacturing processes, fueled by the latest data analysis and digital technologies, have the potential to fundamentally transform the practice of medicine, turning the previously impossible into possible for millions of patients around the world.

We work with colleagues who are always ready to embrace new approaches, change, and development, whose devoted, top-quality work and competence are one of our main assets providing a solid basis for our future scientific achievements.

Thanks to the dedicated efforts of our employees, Sanofi has evolved into a leading healthcare company over the past 50 years with an exceptionally rich legacy in scientific discoveries that improve people's lives.

On the following pages, you can read about this exceptional legacy and what we do to make our common future even healthier and happier.

DR. TAMÁS RÓNAI
Country Lead Hungary



About us

As an innovative, global biotechnology company, we are driven by the purpose of improving people's lives and to this end, we chase the miracles of science. With some **91 thousand employees in 90 countries of the world**, we are committed to no less than transforming the practice of medicine and using our results to turn the previously impossible into possible. We offer

curative and life-quality improving therapeutic solutions for millions of people worldwide, along with vaccines that provide protection against infections and often save lives.

We pursue our activities in a sustainable manner and play an active role in numerous fields with great importance to society.

World presence



By playing a useful part in the local economies and communities, our employees across the globe work towards contributing to people's general health and delivering

products, health solutions, and vaccines that help preserve and restore health.

Our products are available in 170 countries.

Present in more than
*170 countries*¹

Some
91,000
employees worldwide

EUR 43
billion net sales at
Group level in 2022

Sanofi in Hungary



Building on the domestic pharmaceutical manufacturing traditions of more than 100 years, our global biotechnology company has a significant presence in Hungary, even by European standards. In terms of sales, we are the **second largest pharmaceutical manufacturer** in the country*. We rank 22nd among exporters, and regarding annual sales, we are the 34th largest company in Hungary**.

We **employ 2,000 people** in the fields of pharmaceutical manufacturing, commerce, clinical research, business services and distribution.

The more than **900 employees** at our dynamically expanding international service center, the Sanofi Budapest Hub, provide professional services in the fields of finance, HR, regulatory, digital operations, and strategic processes in **12 different languages** for Sanofi's affiliates worldwide.

**In terms of sales by value - Source: IQVIA National Dataview Sell-in data. August 2023 (sales at producer price)*

***Based on 2022 sales / export sales - Source: HVG Top50 ranking 2023*

2,000
employees
in Hungary

~ 1,350
employees provide support
for our office, commercial
and sales activities

~ 650
blue collars in support of
our industrial activities

At the helm of innovation

Be it global business services or ampoule production, our employees deliver innovative, top-quality work in all expert areas, even by international standards.

BUSINESS UNIT ACTIVITIES:

The manufacture and distribution of our innovative and over-the-counter (CHC) products are organized into four global business units: **Specialty Care, Vaccines, General Medicines and Consumer Healthcare***.

**As of 2021, our Consumer Healthcare Global Business Unit has been operating as a standalone unit manufacturing and selling our CHC products.*

OUR ACTIVITIES:

- Sale of innovative and CHC products
- Medicine, syringe and ampoule production
- Global business services
- Commercial support functions (administration, marketing, sales)
- Clinical research



Specialty Care

Specialty Care is one of Sanofi's most dynamically developing business units. Our aim is to contribute to people's good health with the help of science and innovation and to assume a leading role in immunology, oncology, and the treatment of rare diseases and multiple sclerosis.


IMMUNOLOGY

Millions all over the world suffer from diseases caused by the altered functioning of the immune system, and the number of those affected is on the rise. Chronic type 2 inflammation, the result of a hyperactive immune system, may affect a number of organs that come into direct contact with the environment and may considerably compromise the quality of life of patients and their relatives, placing a significant burden on those concerned.

We, at Sanofi are committed to providing the appropriate treatment for patients and ensuring that our advances in the field of immunology offer them access to increasingly customized therapeutic options.

ONCOLOGY

Cancer is the second most common cause of death worldwide, imposing an enormous burden on patients, their relatives, and the healthcare workers providing care alike. The stories of cancer patients inspire us to develop new therapeutic options and to facilitate access to treatments giving them a chance to live longer, whether it be multiple myeloma or lung cancer.



RARE DISEASES


The colleagues working with rare diseases in cooperation with healthcare professionals focus on four therapeutic areas to help reduce the diagnostic timeframe for patients with rare diseases which often takes years. This way, patients can access the available treatments in time, so patients, their families, and society will be less burdened.

We, at Sanofi have long been committed to the treatment of rare diseases. This pioneering work started some 35 years ago when we developed our first enzyme replacement therapy for hereditary (1) **Gaucher disease** where a specific enzyme fails to function properly. Since then, the range of biological therapies that can be administered to treat

rare diseases has been expanding continually. For example, an enzyme replacement therapy for ASMD (acid sphingomyelinase deficiency) and a therapy to treat patients suffering from a rare, life-threatening blood disorder, autoimmune thrombotic thrombocytopenic purpura (TTP) are now both available. Moreover, since the 2000's Hungarian patients can receive enzyme replacement therapies to treat (2) Pompe disease that leads to muscle weakness and respiratory symptoms, (3) an X-linked metabolic disorder, **Fabry disease**, and (4) **MPS I disease**. All new therapies brought about a major breakthrough in the treatment of such diseases.

MULTIPLE SCLEROSIS

There are more than two million people suffering from multiple sclerosis worldwide. In this neurological disease, the immune system launches an attack on healthy tissues in the brain and the spinal cord, and the disease may become more severe in certain patients over time. We are determined to help people with neurological disorders, including MS patients, by inventing new treatments and developing patient care. Since the introduction of our portfolio in 2012, we have been at the forefront of MS therapies. Currently, we offer two treatments (high-efficacy therapy and platform therapy) in more than 80 countries for patients.



Vaccines

We believe in a world where no one suffers or dies from a disease that can be prevented by vaccination. Our Vaccines Business Unit works towards this goal day by day. We aim to provide protection against infectious diseases by developing safe and effective vaccines.

We offer vaccines worldwide against nearly 20 types of infectious diseases caused by bacteria or viruses. We manufacture more than 1 billion doses of vaccines every year to enable the vaccination of over 500 million people around the world.

We also assign priority to fighting the flu, helping millions of people with prevention worldwide year by year.

Our vaccine launched in 2022 prevents meningococcal infection which causes bacterial meningitis. This disease claims lives every year in Hungary or it can cause severe lifelong sequelae. Because even one case is too many...

Our aim is to reduce the number of vaccine preventable diseases, thereby improving the chances for a full and healthy life in every age group.





General *Medicines*

Our General Medicines Business Unit established in 2020 merges our formerly independent diabetes and cardiovascular areas and our traditional, well-known medicinal products, with special focus on the markets of developed countries.

DIABETES & CARDIOVASCULAR TREATMENT

A total of **537 million** adults¹ live with diabetes worldwide, including around **700 thousand**² diabetes patients in Hungary. As the number of patients with diabetes has been continuously increasing, diabetes care has become a global issue. We, at Sanofi have a hundred years of experience in diabetes care. We are committed to fighting this disease to ensure the most effective treatment possible and reduce the risk of complications. With our state-of-the-art insulin therapy and innovative administering devices, we offer solutions to improve the quality of life of diabetes patients. Our ambition in the spirit of safety, efficacy and innovation is to continuously develop our products and services.

Blood clots (thrombosis) are one of the leading causes of cardiovascular death. Preventing and treating thrombosis and reducing its complications is a huge burden for patients, healthcare and society. Blood clots can develop on both the arterial and venous side. Civilisation, an ageing population and cancer, among other factors, are responsible for the increasing incidence of venous thromboembolism. Small molecule heparins are used to prevent and treat venous thrombosis. Our anticoagulant has indications in seven therapeutic areas, which from 2021 include the treatment of patients with cancer who have suffered a thrombosis and the prevention of recurrence of thrombosis. Since 2005, the production of these injections are produced at our Csanyikvölgy plant, which supplies patients not only in Hungary but also in many other European countries.

¹ Source: *IDF Diabetes Atlas 2021*

² Source: <https://diabetesatlas.org/data/en/country/91/hu.html>


Consumer Healthcare*

CONSUMER HEALTHCARE PRODUCTS

Available at pharmacies, online pharmacies, drugstores and gas stations, our consumer healthcare (CHC) products are an important part of our company's portfolio. We are proud to have a quality product portfolio in various categories, thereby being able to offer efficient solutions for many. Be it pain management, common cold, magnesium deficiency, allergies, digestive issues, vitamin replenishment or spasm relief, the wide

range of our consumer products provides the means to manage the complaints of patients or helps prevent diseases.

Based on consumer decisions, we have a number of products with a strong presence in the Hungarian consumer healthcare drug market. This is clearly highlighted by the fact that in 2023, 5 out of the 10 most popular products in Hungary were Sanofi products.²



In 2023, the 10 most popular products in Hungary featured **5 Sanofi products²**

Sanofi Consumer Healthcare has been **the leader for more than 10 years** in the market of CHC products¹

* A standalone business unit
1 Source: IQVIA Full WHS, 09/2023 national data, combined channel, Sell-In Value, Sell-In Unit
2 Source: IQVIA FullPTR, 09/2023 national data, Sell-Out Value



Pharmaceutical manufacturing using geothermal energy at Veresegyház

The main activity of our *Veresegyház Site* is the production and packaging of **solid tablets, pills and capsules**.

We manufacture products of **15 product families**, these are mainly consumer health-care products but our portfolio includes prescription and generic medicinal products as well.

Our site supplies **45 different markets** with our products for pain management, spasm relief, and stress management, such as products of the Magne B6®, No-Spa®, Algoflex®, Dolipran* product families.

The **380 employees** at the Veresegyház Site deliver **150-175 million boxes** of medicinal products to patients every year.

** Not available on the Hungarian market*



OUR FIELDS OF ACTIVITIES

Syringe and ampoule production in Csanyikvölgy

In Csanyikvölgy near Miskolc, with the help of close to **500 employees** and using cutting-edge technology, we produce more than **200 million injection** units a year, helping to treat millions of patients in Hungary and in the **60 countries** around the world to which we export our products.

Situated in the picturesque Bükk National Park, our production site pays particular attention to the protection of its surroundings and the reduction of its ecological footprint, in addition to meeting health and safety requirements. **2016 marked the 30th anniversary** of our site and the launch of a new investment project; together with this project the developments at Sanofi's Csanyikvölgy Site total over HUF 30 billion.

INVESTMENTS

HUF 50,7 billion until 2023

HUF 12 billion

by 2022 over
the last 5 years

By virtue of our world-class production technology enabled by our continuous investment efforts and our ambition for operational excellence, we have become a solid point of stability in global pharmaceutical production, being the manufacturer of a product of strategic importance such as our anticoagulant injection of which **2 billion syringes had been filled in and packaged by 2022 since the starting date of production**. Over the past seven years, we have installed two high-tech, high-capacity prefilled syringe production lines in two phases, increasing our syringe production capacity by 2.5 times. The Hungarian government awarded **HUF 1.2 billion** in investment grants to support the development project launched in 2021 to modernize the site. Innovation will continue, with active investment currently exceeding HUF 2 billion.





On the way to our customers

In addition to ensuring the supply of pharmaceuticals in Hungary, our distribution centre in Nagytétény, operated by our external partner, is also responsible for product distribution in Central and Eastern Europe and the Asia-Pacific region, providing pharmaceutical warehousing and secondary repackaging services. The logistics tasks related to export activities (customer service, freight forwarding, stock and master data management) are performed by Sanofi.

Sanofi *Budapest Hub*

Since its launch in 2019, the Sanofi Budapest Hub has been the fastest growing and a continuously expanding entity of our Hungarian affiliate. More than **900 colleagues** work in the Váci Greens office campus, providing professional services in **12 languages** globally for Sanofi's affiliates in the fields of finance, customer support, human resources, regulatory, clinical studies, process automation, data analytics and digital operation.

Our international service center, which operates as a center of expertise and competence, provides a broad range of financial and employee services to support the employees, partners, resellers of our diverse global Group in their everyday work. Holding digitalization and innovation in the highest regard, we also develop our internal processes continually and, in addition to our services, support the company globally by providing business solutions.



As part of the Sanofi Global Business Operations, our employees help our colleagues in their everyday work in cooperation with various international teams so that the areas responsible for development, manufacturing, and commerce can focus on their core activity and thereby enable patients to access the healthcare solutions that are important to them as soon as possible.



Hungarian *Marketing, Sales and Support Functions*

The headquarters as well as the administrative and marketing and sales center of our Hungarian affiliate are located in Building “E” of the Váci Greens office campus in Budapest where more than 250 employees carry out the marketing and sales responsibilities of our four business units and lend administrative support for business activities.



Clinical trials

Our team organizing clinical trials also works in **the Váci Greens office building** in Budapest. As a result of their efforts, **35 clinical trials** with more than **900 patients** enrolled were conducted in Hungary in 2022 at more than 180 domestic sites.



The results of these trials were a major global contribution to ensuring that our innovative products are made available to patients as soon as possible. Our company cooperates with all four Hungarian universities of medical sciences in the field of clinical trials.

Responsible employer

We work tirelessly to provide a solid, safe and quality workplace for our employees in a stimulating and modern office environment equipped with advanced industrial technologies that makes them happy to come to work. We respect and facilitate work-life balance by providing specific company programs. The option of **part-time work**, a **flexible work schedule**, and **work from home** for number of days above the market average all serve these endeavors.

Pursue *Progress.*
Discover *Extraordinary.*



Both parents qualify for a **paid leave of 14 weeks when caring for a child**. We have an annual comprehensive **screening test** in place to help our employees preserve their health.

With our **Employee Assistance Program**, our employees and their families can seek mental, legal and financial advice free of charge.



Together for health

AGE DISTRIBUTION OF
EMPLOYEES IN HUNGARY:



DISTRIBUTION
BY HEADCOUNT AND GENDER



2,000



61%



39%



●

With responsibility
for health,
for our employees,
for local communities,
for our common future

●





Our social *commitment*

We, at Sanofi not only believe that we can always do more, but we also act. We seek to contribute to making our planet more livable, sustainable, broadening the range of available healthcare solutions, and supporting disadvantaged communities all over the world, and to operate as an inclusive, accepting workplace.

Through our Sanofi Global Health nonprofit organization, we ensure access to 30 essential medicinal products by those in need in 40 countries around the world and donate 100 thousand units to patients with rare diseases. We continuously strive to develop appropriate medicinal products to fight childhood cancer, to eradicate polio and African trypanosomiasis (sleeping sickness) everywhere in the world.

Our employees work in a supportive, stimulating environment where they can fully tap their potential and where women and men fill leading positions in equal proportions. In the next years, we will continue to pay special attention to the eco-conscious

packaging of our products, to increasing the ratio of renewables, and to ensuring carbon neutrality both in production and during the operation of our fleet vehicles.

In line with the “Think globally, act locally” principle, we run programs in diverse areas also in Hungary in the spirit of corporate social responsibility for the sake of health education, the control of diabetes and cardiovascular diseases, prevention, and self-care.

Our new employee volunteering program has not only boosted our corporate volunteers’ engagement and their numbers, but also our cooperation with NGOs and its effectiveness. We are guided by our own conviction in the efforts we make to benefit society and the environment—we, at Sanofi believe that we must continuously act to build a healthy and balanced life. Together, we can do more.

ANDREA ASZTALOS
Communications Director

THE STRATEGIC PILLARS OF OUR SOCIAL COMMITMENT

As a global pharmaceutical company, we have a responsibility to get involved in addressing the most pressing global health and social challenges.

Our integrated Corporate Social Responsibility Strategy aims to contribute to building a healthier, more livable and sustainable world by providing the most deprived social groups with access to healthcare and making efforts to address unmet needs.

To implement this strategy, we set up the **Sanofi Global Health Unit** at the global level in 2021 as the Group's non-profit unit to improve access to healthcare through the distribution of

pharmaceutical products and to establish and strengthen local healthcare systems in countries with the lowest GDP per capita.

Another global entity of our Group is the **Sanofi's Children Association** (Enfants de Sanofi) which offers moral and material support to any Sanofi employee anywhere in the world, hence also in Hungary, who faces problems in terms of the health, social situation or schooling of their children (from birth until 25 years of age).

Integrated into our business strategy, our commitment to society is based on four key pillars implemented to facilitate positive change and have a favorable impact on our planet and our societies:

Affordable Access

- 2 Billion people** lack access to quality medicine and healthcare
- Non-profit business unit Sanofi Global Health to provide **30 essential medicines** to **40 of the world's poorest countries**
- 100k** 100,000 vials to be donated to patients with rare diseases
- Global Access Plan** for all new products two years after launch

Healthy Planet

- +4°C** worst-case climate change scenario with significant impacts on health
- Eco-design** for all new products by 2025
- Renewable electricity** on all sites by 2030
- Blister free** vaccine packs by 2027
- Carbon neutral** car fleet by 2030

Inclusive Workplace

- Employee engagement** is critical for Sanofi's success
- 50:50 gender ratio** in top 2,000 leadership team by 2025
- Company-wide** volunteering program
- Social impact** integrated in leaders' career development

Vulnerable Communities

- Vulnerable communities** still in need worldwide
- Eliminate sleeping sickness** by 2030
- Eradicate polio**
- Develop treatments** for childhood cancers

OUR ESG* PERFORMANCE

In 2022, Sanofi was recognized as the most committed company to sustainability in the ESG assessment of Standard & Poor's Global Ratings (S&P). We take great pride in our outstanding achievement in terms of our commitment to providing access to pharmaceutical products when compared to other actors of the global corporate scene.



* ESG, i.e. Environmental, Social, and Governance, are a set of criteria designed to enable potential investors to identify companies to potentially invest in. Corporate Social Responsibility (CSR) is a (mostly) self-regulatory approach whereby companies seek to manage their impact on society (environment, economy and people).

Our corporate social responsibility *programs in Hungary*

THE ROAD TO HEALTH PROGRAM

To control some of the leading causes of death in Hungary, including cardiovascular diseases, hypertension and diabetes, Szent Ferenc Hospital in Budapest launched its initiative called “Road to Health Program” in 2015 with professional support from Sanofi aimed at improving the general health of the Hungarian population and, in this context, encourage families to do physical exercise and have a more physically active lifestyle.

The program targets various generations at the same time, based on different aspects resulting from their situation and needs. For older people, guided hikes are offered with the main purpose of health maintenance and rehabilitation, while for younger generations, the primary focus is on prevention.

By establishing specific hiking trails (“educational trails”), in addition to being a leisure activity, the program also helps prevent widespread diseases such as cardiovascular diseases, diabetes, and hypertension, improves stamina and last but not least contributes to maintaining mental health. Hikers get to learn about some basic health indicators and measurement techniques and use instruments available for rent to do individual health checks during the hike, contributing to the development and enhancement of health awareness.

Over the last few years, we established educational trails at 7 locations in total in Budapest and across the country (Kis-Hárs-hegy, Normafa, Farkas-erdő in Újpest, Csanyikölgy, Veresegyház, Kékes, Szépvölgy) under the Road to Health Program. Considering the success and justification of the program, we want to expand it to cover more locations across Hungary, with future plans for the initiative to cover over-the-border areas in the entire Carpathian Basin.



The Road to Health Program won the CSR Hungary Award in the “Shared responsibility — Shared issues” category in 2016 and the “It Speaks to Me! Health Literacy 2020” Award of the Association of Innovative Pharmaceutical Manufacturers.





KIDS

Sanofi is committed to the fight against diabetes. In addition to our state-of-the-art therapies, we aim to promote the health of people in Hungary effectively in the context of Corporate Social Responsibility.

The KiDS program is designed to foster an environment to provide a better understanding of diabetes as early as elementary school, help children with diabetes and improve the ability to prevent type 2 diabetes.

The program was conceived by the International Diabetes Federation (IDF) for elementary-school children as well as their teachers and parents and is supported by Sanofi at the global level.



KiDS raises awareness of diabetes among children through an interactive theme day where lessons are followed by fun exercises. Teachers and parents can broaden their knowledge through technical lectures.

The objective of the program is to foster:

- a better understanding of diabetes,
- support for children with diabetes,
- the ability to prevent type 2 diabetes.

Between 2018 and 2023, 2,804 people participated in KiDS sessions, over 1,500 of them elementary-school children.

It is a source of great pride for us that KiDS educational resources are an important part of the curricula of two national awareness-raising programs developed by Egy Csepp Figyelem Alapítvány for the Hungarian Educational Authority and Hungarian teachers in 2021 (DiabMentor, CukorSuli (Sugar-School)).

The KiDS program was launched in Hungary in 2018. The credit for implementation goes to **Egy Csepp Figyelem Alapítvány***, one of the key NGOs in Hungary addressing diabetes. For the technical adaptation of the program, we benefitted from the expertise of the Hungarian Diabetes Association.

**One Drop of Attention Foundation*

Thus, KiDS has already achieved one of its key goals: being integrated into the Hungarian educational system by enhancing visibility and manageability of diabetes as a public health challenge.



TEENS

For Sanofi, it is key to highlight the importance of self-care at a young age. Therefore, in 2020, we launched the **TEENS program aimed at the health promotion of ages 13 and 14 using digital tools and customized thematic resources.**

TEENS seeks to prevent chronic conditions (obesity, diabetes, cardiovascular diseases and hypertension) by promoting appropriate lifestyle choices. The project is targeted at ages 13 and 14 who are adequately mature to understand the specific knowledge and are concerned with physical and mental changes.

The program is implemented by Egy Csepp Figyelem Alapítvány, one of the key health NGOs in Hungary, as in the case of our KiDS program. In schools joining TEENS, we organize a half-day thematic program for a selected class, with 30 to 35 participants per session.

Sessions comprise interactive lessons, fun quizzes and exercises requiring teamwork and cooperation on the following topics:

- Self-care
- Healthy diet
- Importance of physical exercise
- Mental health

The program was fundamentally designed for personal presence and offline implementation; however, due to the pandemic, in the 2020 pilot year, it took the form of online webinars in a modern, virtual, 3D environment.

Since 2021, the program has been delivered in a face-to-face format, with a total of 287 12 to 14-year old students participating so far.

It was very well received by both the pupils and the teachers involved. Sanofi is committed to strengthening self-care in society and overcoming public health challenges also in the long run.



we volunteer

We at Sanofi have long been committed to helping communities by doing voluntary work, to which our employees have been making valuable contribution for years. Our employees are happy to support causes that facilitate the fulfilment of the commitments we make as a responsible company. We Volunteer, our company-wide employee volunteering program has been launched in accord with this commitment.

We Volunteer embodies Sanofi's commitment to society and enables our employees to take on an active role in volunteering initiatives. To facilitate the latter, our employees in Hungary can take one paid day off a year to engage in a voluntary activity under the program. NGOs can publicize We Volunteer programs on a website where our volunteers can register for the activity they select.

The range of our volunteering programs—trailblazers both at global and country level—changes and expands dynamically, so our employees can address important social issues at different times and locations throughout the year.

Our Corporate Social Responsibility represents a set of special values to shape attitudes, driven by both corporate and individual commitment. A responsible approach to social issues, promoting sensitivity and an active involvement in matters we consider important are our common mission and duty, while also involving valuable, energizing and community-building teamwork.

We are proud of our volunteers with whom together we can do even more.



Our ethical *operation*

CORPORATE TRAINING IN SUPPORT OF COMPLIANCE WITH BUSINESS ETHICS

A company's reputation is one of its most important assets. Accordingly, compliance with business integrity is a top priority for Sanofi which is, amongst other things, a founding member of the professional associations that established the Pharmaceutical Industry Code of Ethics. Every year we conduct awareness raising campaigns and deliver training on the practical aspects of compliance with the core values of business integrity.

In our Code of Conduct, we have formulated strong and firm rules that are in line with the Hungarian legal framework and at the same time communicate Sanofi's values and key ethical principles to all our employees.

Our Code of Conduct is available at:



IMPLEMENTING CORPORATE VALUES IN PROCUREMENT

In cooperation with the Ecovadis auditing firm and with the help of an electronic system for the evaluation of procurement risks, we use questionnaires to audit and appraise our top suppliers on the basis of the extent to which they live up to the values set forth in our CSR strategy, anti-corruption and other policies.

TRANSPARENCY

In line with EFPIA (European Federation of Pharmaceutical Industries Associations) resolutions and our corporate guidelines, and with the prior consent of the concerned parties, we have published the amount of funds we dedicate to our professional cooperation with healthcare professionals.

OUR FIGHT AGAINST COUNTERFEITING

Few people are aware of the dangers and widespread nature of counterfeit medicines. Sanofi works closely with the authorities and uses its own means to combat counterfeiting. A case in point is the dedicated laboratory we operate in France specifically to investigate counterfeit drugs.

In accordance with Commission Delegated Regulation (EU) 2016/161, we introduced serial numbers for all of our prescription drugs in 2019 whereby each and every box of medicinal products is equipped with a unique code to allow their identification, hence the authenticity of a medicinal product can be verified before dispensing the product.

This is another move through which we support the National Board Against Counterfeiting's anti-counterfeit medicine work group as well as public education campaigns which raise people's awareness concerning risks associated with distributing and consuming products of dubious origin.

This brochure is published by:
Sanofi-Aventis Private Co. Ltd.
Building "E", 3rd floor, 133 Váci street, Budapest 1138
MAT-HU-2301469
Close date: 11.01.2024



We chase
the miracles
of science
to improve
people's lives





sanofi

www.sanofi.hu

kapcsolat@sanofi.com

Building "E" 3rd floor

133 Váci Street

Budapest 1138